• Actithera named Steven Kelly chief executive officer, adding him to the board as it moves toward clinical development.
• Kelly previously led Carisma Therapeutics as CEO, steering it to public markets, raising more than $300 million.
• Briggs Morrison took over as board chair; he is CEO of Crossbow Therapeutics, chair of Arvinas, director at CRISPR Therapeutics.
• John Crowley joined as independent director; he was CFO of Centessa Pharmaceuticals ahead of its $7.8 billion acquisition by Eli Lilly.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sofinnova Partners SAS published the original content used to generate this news brief on September 10, 2026, and is solely responsible for the information contained therein.